Bausch Health Companies Inc. (BHC) 2006 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, ladies and gentlemen, and welcome to the third quarter earnings conference call for Biovail Corporation. [OPERATOR INSTRUCTIONS] This conference call is being webcast on the worldwide web Biovail.Com. After Management has completed it's review a question and answer session will be held for research analysts who cover Biovail. After the conference call other participants are encouraged to follow-up with the Company by calling 905-286-3000 and asking for Investor Relations. [OPERATOR INSTRUCTIONS] As a reminder a replay of this Conference Call will be available until 7:00 p.m. Eastern Time on Thursday, November 16, 2006, by dialing 416-695-5800, Toronto and international callers and 1-800-408-3053 for U.S. and Canada , using access code 3201838 followed by the number sign.

    各位女士、先生,早安,歡迎參加 Biovail Corporation 第三季財報電話會議。[OPERATOR INSTRUCTIONS] 本次電話會議將於全球網路 Biovail.Com 進行網路直播。管理階層完成回顧後,將為追蹤 Biovail 的研究分析師舉行問答時段。會後亦鼓勵其他與會者致電 905-286-3000 並洽詢投資人關係部門,以便與公司後續聯繫。[OPERATOR INSTRUCTIONS] 提醒各位,本次電話會議的重播將提供至 2006 年 11 月 16 日(星期四)東部時間晚上 7:00 止,多倫多及國際來電者請撥 416-695-5800,美國及加拿大來電者請撥 1-800-408-3053,並輸入存取碼 3201838 後按井字鍵。

  • On behalf of speakers who follow investors are cautioned that the presentations and responses to questions may contain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and which comprise forward-looking information within the meaning of the Safe Harbor Provisions of Canadian provincial security laws. Forward-looking statements involve risks and uncertainties and undue reliance should not be placed on such statements. Certain material factors or assumptions are applied in making forward-looking statements. Actual results may differ materially from those expressed or implied in such statements. Forward-looking statements include but are not limited our goals, targets, strategies, intentions, plans, beliefs, estimates, expectations, outlooks, and understatements which contains language such as believe, anticipate, expect, intend, plan, will, may, and other similar expressions.

    代表後續發言者提醒投資人注意,簡報內容及對提問的回覆可能包含美國 1995 年《私人證券訴訟改革法》所定義之前瞻性陳述,並構成加拿大各省證券法「安全港條款」意義下的前瞻性資訊。前瞻性陳述涉及風險與不確定性,不應對此類陳述過度依賴。在作出前瞻性陳述時,會採用若干重大因素或假設。實際結果可能與該等陳述所明示或暗示者有重大差異。前瞻性陳述包括但不限於我們的目標、指標、策略、意圖、計畫、信念、估計、預期、展望及(原文)understatements,並包含如 believe、anticipate、expect、intend、plan、will、may 等及其他類似用語。

  • For additional information about the material factors or assumptions underlying such statements and about the material factors that may cause actual results to vary from those expressed or implied in such statements, please consult the Company's earnings and guidance news release dated November 9, of 2006, that are available on the Company 's website as well as it's filings with the Securities and Exchange Commission and the Ontario Securities Commission including the Risk Factors detailed in it's most recent Annual Report on Form 20-F item 3D. The Company does not undertake to update any forward-looking statements.

    如需了解支撐該等陳述之重大因素或假設的更多資訊,以及可能導致實際結果與該等陳述所明示或暗示者不同的重大因素,請參閱公司於 2006 年 11 月 9 日發布的財報與財測新聞稿(可於公司網站取得),以及公司向美國證券交易委員會與安大略證券委員會所提交之文件,包括公司最近一期 Form 20-F 年報第 3D 項所詳述的風險因素。公司不承諾更新任何前瞻性陳述。

  • Investors are also advised to consult the description of non-GAAP financial measures related to net income and earnings per share excluding specific items detailed in the Company's November 9, earnings news release. At this point I would like to turn the call over to Ken Howling, Senior Vice President of Finance and Corporate Affairs for Biovail Corporation. Mr. Howling will moderate today's call.

    亦提醒投資人參閱公司 11 月 9 日財報新聞稿中所詳述之非 GAAP 財務衡量指標的說明,該等指標與排除特定項目後之淨利及每股盈餘相關。接下來我想把電話交給 Biovail Corporation 財務與企業事務資深副總裁 Ken Howling。Howling 先生將主持今天的電話會議。

  • - SVP-Fin., Corp. Affairs

    - SVP-Fin., Corp. Affairs

  • Thank you, Operator, and good morning, everyone. On be half of Biovail, thank you for joining us this morning for our quarterly conference call during which we will provide additional insight into the financial results and operating highlights for the third quarter and first nine months of 2006. Joining me on today's call are Dr. Douglas Squires, Chief Executive Officer of Biovail Corporation; Charles Rowland, Senior Vice President and Chief Financial Officer; Dr. Peter Silverstone, Senior Vice President, Medical and Scientific Affairs; also on the call today is Wendy Kelley, Senior Vice President , General Counsel, and Corporate Secretary.

    謝謝接線員,各位早安。我謹代表 Biovail,感謝各位今天早上參加我們的季度電話會議;會中我們將就 2006 年第三季及前九個月的財務結果與營運重點提供更多洞見。今天與我一同出席的有 Biovail Corporation 執行長 Douglas Squires 博士;資深副總裁兼財務長 Charles Rowland;醫學與科學事務資深副總裁 Peter Silverstone 博士;此外,今天也有資深副總裁、總法律顧問兼公司秘書 Wendy Kelley 出席。

  • They will be available along with myself to participate during the question and answer session with research analysts following our prepared remarks. As always, we will try to get to an many questions as possible while limiting the call to approximately one hour. After the conference call other participants are encouraged to follow-up with the Company by calling 905-286-3000 and asking for Investor Relations. Doug would you like to begin, please?

    在我們的準備發言結束後,他們將與我一同在研究分析師的問答時段中參與回覆。一如往常,我們會在將通話時間控制在約一小時的前提下,盡可能回答更多問題。會後亦鼓勵其他與會者致電 905-286-3000 並洽詢投資人關係部門,以便與公司後續聯繫。Doug,請您先開始好嗎?

  • - CEO

    - CEO

  • Thank you, Ken. Good morning, everyone. Thank you for joining us this morning. I am pleased do provide you with an in depth review of Biovail's operational performance for the third quarter of 2006. An ongoing goal for us is to execute against our stated financial and operational objectives, and once again, for the ninth consecutive quarter, we have met that committment.

    謝謝你,Ken。各位早安。感謝各位今天早上加入我們。我很高興就 Biovail 於 2006 年第三季的營運表現,向各位提供深入回顧。我們持續的目標之一,是落實既定的財務與營運目標;而且再次地,連續第九個季度,我們達成了這項承諾。

  • For the first three months ended September 30, 2006, Biovail generated record revenues and robust cash flows on operations. Overall, our products performed very well, in many cases, they met or exceeded our expectations while continuing to grow market share. This strong performance has also left us well positioned to invest in strategic growth initiatives for the business while maintaining our dividend policy. Clearly, the investments we have made in our business combined with the transformations that we have made during the past 24 months to the ways we do business have played a major role in our performance. During this time, we have remained conscience and optimistic about the dynamic nature of the pharmaceutical industry and in turn optimistic of Biovail's role and ability to add value to this industry.

    截至 2006 年 9 月 30 日止的前三個月,Biovail 創下營收新高,且營運現金流強勁。整體而言,我們的產品表現非常出色;在許多情況下,不僅符合甚至超越我們的預期,同時持續提升市占率。這樣的強勁表現也使我們在維持股利政策的同時,具備良好條件投資於業務的策略性成長計畫。顯然,我們對業務所做的投資,加上過去 24 個月我們在營運方式上的轉型,對我們的表現發揮了重大作用。在此期間,我們對製藥產業的動態本質始終保持審慎且樂觀,並因此對 Biovail 在此產業中的角色與創造價值的能力同樣抱持樂觀。

  • One of the on the omnipresent realities of a pharmaceutical industry is the generic ablation of drug products. As you will recall, in early August, the United States District Court Of the Central District of California surprisingly granted, in part, Anchen's motion for summary judgment with respect to patent infringement litigation relating to Wellbutrin XL. The Court ruled that Anchen's abbreviated new drug application did not infringe on Biovail's patents but denied the portion of Anchen's motion that sought to invalidate Biovail's patent.

    製藥產業中一項無所不在的現實,便是藥品面臨學名藥的侵蝕。各位或許記得,8 月初,美國加州中區聯邦地方法院出人意料地就與 Wellbutrin XL 相關的專利侵權訴訟,部分准許 Anchen 提出的簡易判決動議。法院裁定 Anchen 的簡化新藥申請(ANDA)未侵害 Biovail 的專利,但駁回了 Anchen 試圖使 Biovail 專利無效的那部分動議。

  • Let me now take a few minutes to provide an update on where things stand with patent infringement litigation between Biovail and Anchen. In mid September, Biovail filed a formal appeal of the United States District Court for the Central District of California decision in Federal Appeals Court. It is impossible for us to predict exactly when the case will be resolved but it's quite possible that the legal process could take a year or longer.

    接下來我用幾分鐘更新 Biovail 與 Anchen 之間專利侵權訴訟的最新進展。9 月中旬,Biovail 已就美國加州中區聯邦地方法院的裁決,正式向聯邦上訴法院提出上訴。我們無法預測案件究竟何時能結案,但法律程序很可能需要一年或更久。

  • There are, of course, a number of other factors that may impact the entry of generic competition to Wellbutrin XL. Among them, before Anchen can launch a generic version of Wellbutrin XL in the U.S. market they must first receive final approval for it's abbreviated new drug application from the United States Food and Drug Administration. Also, the FDA has yet to rule on either of the two citizens petitions filed by Biovail. The first, filed in March, 2003, requests that the FDA require that if an ANDA filer amends it's ANDA, such that it's Paragraph four certification is no longer accurate, the ANDA filer must recertify to the NDA holder and patent owner with respect to each such ANDA amendment. After receiving tentative approval, Anchen filed with the FDA an amendment that Biovail believes reinforces the merit of it's citizens petition and could impact the analysis of Anchen's patent infringement.

    當然,還有許多其他因素可能影響 Wellbutrin XL 面臨學名藥競爭的進入時點。其中之一是,在 Anchen 能於美國市場推出 Wellbutrin XL 的學名藥版本之前,必須先取得美國食品藥物管理局(FDA)對其簡化新藥申請(ANDA)的最終核准。此外,FDA 迄今尚未就 Biovail 提出的兩份公民請願(citizens petitions)作出裁定。第一份於 2003 年 3 月提出,請求 FDA 要求:若 ANDA 申請人修訂其 ANDA,致使其第四段落認證(Paragraph four certification)不再正確,則 ANDA 申請人必須就每一項該等 ANDA 修訂,向 NDA 持有人及專利權人重新作出認證。在取得暫定核准後,Anchen 向 FDA 提交了一項修訂;Biovail 認為該修訂強化了其公民請願的正當性,並可能影響對 Anchen 專利侵權的分析。

  • The fundamental purpose of a second citizens petition filed in December 2005 was to ensure that generic versions of Wellbutrin XL are safe and effective as the innovator product. Let me remind everyone that we believe that it is critical that the FDA require that any abbreviated new drug application for a generic version of Wellbutrin XL satisfy the following four criteria--One, all bioequivalents trials should calculate and evaluate parameters based on concentrations of the parent drug and active metabolites. Two, any generic formulation should be shown based on the above criteria to be bioequivalent to Wellbutrin XL -- to Wellbutrin XL and the sustained release and the immediate release Bupropion. Three, the bioequivalent study as described above should be conducted at steady state evaluating the performance of the dosage form based on a number of metrics including area under the curve, maximum concentration on C-Max, and minimum concentration or C-Min. Fourth, data used in the FDA's in vitro approach for evaluating the effect of alcohol on the performance of controlled release dosage form should be required to ensure the absence of dose data, if the drug is consumed with alcohol. By that, I mean that some controlled release formulations can rapidly release or dump large amounts of drug in the presence of alcohol.

    2005 年 12 月提出的第二份公民請願書,其根本目的在於確保 Wellbutrin XL 的學名藥版本與原廠產品同樣安全且有效。我想提醒各位,我們認為 FDA 至關重要的是:任何 Wellbutrin XL 學名藥的簡化新藥申請(ANDA)都必須符合以下四項標準——第一,所有生體相等性試驗都應以母體藥物及其活性代謝物的濃度為基礎來計算並評估相關參數。第二,任何學名藥配方都應依上述標準證明其與 Wellbutrin XL——亦即與 Wellbutrin XL 以及緩釋與速釋之 Bupropion——具有生體相等性。第三,上述生體相等性研究應在穩態下進行,並以多項指標評估劑型表現,包括曲線下面積(AUC)、最高濃度(C-Max)以及最低濃度(C-Min)。第四,FDA 以體外方法評估酒精對控釋劑型表現之影響時所使用的數據,應被要求用以確保在與酒精併用時不會發生劑量傾瀉(dose dumping)。我的意思是,有些控釋配方在酒精存在時可能會迅速釋放或傾瀉大量藥物。

  • Additionally, there are a number of commercial factors that may affect the potential timing of when Anchen may launch a generic version of Wellbutrin XL, assuming that it receives final FDA approval. These commercial factors include Anchen's ability and the ability and willingness of it's manufacturing and/or distribution partner to launch at risk, pending a course decision on Biovail's appeal, and Anchen's ability to manufacture sufficient quantities to support such a launch.

    此外,若 Anchen 取得 FDA 最終核准,仍有若干商業因素可能影響其推出 Wellbutrin XL 學名藥版本的潛在時點。這些商業因素包括:Anchen 的能力,以及其製造及/或經銷合作夥伴在 Biovail 上訴案尚待法院裁決期間,是否有能力且願意承擔風險先行上市;以及 Anchen 是否有能力生產足夠數量以支撐此類上市。

  • Given the potential near term loss of exclusivity for Wellbutrin XL, and a period during which our new products cannot entirely offset these lost sales, we are scrutinizing all aspects of our business and will take an aggressive line on cost containment. Everything is on the table with the exception of our continued investment and high value pipeline programs. Biovail's executive management team is currently assessing every aspect of our operations to reduce costs and increase operating efficiencies, and while it was difficult to predict exactly when generic formulations of Wellbutrin XL may enter the market, or to what extent competitors may be able to supply the market, Biovail will position it's business to minimize the negative impact this could have on the Company 's operating margins while continuing to invest in our pipeline programs. We anticipate being in a position to make announcements related to this review before the end of the year.

    鑑於 Wellbutrin XL 可能在短期內喪失獨家銷售權,且在一段期間內我們的新產品無法完全抵銷這些流失的銷售額,我們正審視業務的各個面向,並將採取積極的成本控管立場。除我們持續投資及高價值的產品線研發計畫外,其他一切皆可納入考量。Biovail 的高階管理團隊目前正評估我們營運的每一個面向,以降低成本並提升營運效率;雖然難以精確預測 Wellbutrin XL 的學名藥配方何時可能進入市場,或競爭者在多大程度上能供應市場,Biovail 將調整其業務布局,以在持續投資產品線研發計畫的同時,將此事對公司營業利益率可能造成的負面影響降至最低。我們預期可在年底前就此項檢討發布相關公告。

  • Biovail remains committed to advancing our product development pipeline by accelerating those programs with the most value. To this end, we are currently in discussions with a number of companies regarding several of our ongoing development programs with the intention of accelerating these programs in a very cost effective manner. We are also assessing outlicensing opportunities for a number of products that we have developed that are based on our oral disintegrating tablet technology. Research and Development remains an integral part of our future. At this time, I would like to ask Dr. Peter Silverstone, Biovail's Senior Vice President, Medical and Scientific Affairs, to provide you with an update on the status of some of our pipeline programs. Peter?

    Biovail 仍致力於推進我們的產品開發產品線,並加速最具價值的計畫。為此,我們目前正與多家公司就數項進行中的開發計畫進行討論,目標是以非常具成本效益的方式加速這些計畫。我們也正在評估將若干以我們口腔崩散錠(oral disintegrating tablet)技術為基礎所開發產品的對外授權(outlicensing)機會。研發仍是我們未來不可或缺的一部分。此刻,我想請 Biovail 醫學與科學事務資深副總裁 Peter Silverstone 醫師,向各位更新我們部分產品線研發計畫的進度。Peter?

  • - SVP, Medical, Scientific Affairs

    - SVP, Medical, Scientific Affairs

  • Thank you, Doug. Good morning, everyone. As you're aware, Biovail has a number of products in development. In the past these initiatives have been referred to in a variety of ways. Going forward, to clarify each project and to simplify communication each of these is now being given a specific identifier, consisting of the letters BVF followed by a three number code. As I spend a few minutes updating you on some of the recent developments, I will use these codes.

    謝謝你,Doug。各位早安。如各位所知,Biovail 有多項產品正在開發中。過去這些計畫曾以不同方式稱呼。未來,為了釐清各項專案並簡化溝通,我們現在為每一項專案指定一個特定識別碼,由字母 BVF 加上三位數代碼組成。接下來我將用幾分鐘向各位更新近期部分進展時,會使用這些代碼。

  • As has been previously discussed, Biovail has developed a Novel Bupropion sort referred to now as BVF 033. In keeping with the timeliness, previously publicly outlined by Dr. Squires, in late September, 2006, Biovail submitted a new drug application to the FDA the BVF 033, for the treatment of depressive illness in adults. Biovail believes that BVF 033 may offer a superior safety profile to Bupropion hydrochloride, the compound upon which Wellbutrin XL is based. Dose dumping in the presence of alcohol also presents significant risks to patients and is of increasing concern to regulatory parties such as the FDA. In the presence of alcohol, BVF 033 has a more favorable release profile than other long acting Bupropion formulations and does not dose dump. This Novel formulation of Bupropion is also being used as the platform for our Bupropion combination product, BVF 045. Biovail believes that BVF 045 which combines drugs with different mechanisms of action may provide physicians a single tablet option that may be particularly effective in the treatment of depression.

    如先前所述,Biovail 已開發一種新型 Bupropion 鹽類,現稱為 BVF 033。依照 Squires 醫師先前公開說明的時程,Biovail 於 2006 年 9 月下旬向 FDA 提交 BVF 033 的新藥申請(NDA),用於治療成人憂鬱症。Biovail 認為,BVF 033 可能較作為 Wellbutrin XL 基礎成分的鹽酸 Bupropion 具有更佳的安全性特徵。在酒精存在下的劑量傾瀉亦會對病患造成重大風險,並日益引起如 FDA 等監管機構的關切。在酒精存在下,BVF 033 的釋放特性較其他長效 Bupropion 配方更為有利,且不會發生劑量傾瀉。此一新型 Bupropion 配方亦被用作我們 Bupropion 複方產品 BVF 045 的平台。Biovail 認為,結合不同作用機轉藥物的 BVF 045,可能為醫師提供單一錠劑的選擇,並可能在治療憂鬱症方面特別有效。

  • In keeping with Biovail's committment to develop a pain management franchise with Canada, Biovail filed a new drug submission with a therapeutics product directorate in Canada in late August for BVF 127. This is a once daily extended release Tramadol for the management of moderate to moderately severe chronic pain in adults. On Monday of this week, we received word from TPD that our NDX for BVF 127 has been accepted for review. Consistent with our belief that our ongoing development work with combination products offers significant upside potential and further to our previously stated intention to accelerate key research programs, I'm pleased to inform you that Biovail has initiated Phase III clinical trials for BVF 146, a once daily combination product, comprised of Tramadol hydrochloride and an undisclosed non-steroidal antiinflammatory drug. We believe that BVF 146 may provide physicians and healthcare practitioners with a Novel treatment option for patients who suffer from moderate to moderately severe chronic pain.

    為延續 Biovail 致力於在加拿大建立疼痛管理產品線(franchise)的承諾,Biovail 於 8 月下旬就 BVF 127 向加拿大治療產品司(Therapeutic Products Directorate, TPD)提交新藥申請。此產品為每日一次的 Tramadol 緩釋劑型,用於成人中度至中重度慢性疼痛之管理。本週一,我們收到 TPD 通知,BVF 127 的 NDS 已獲受理並進入審查。基於我們相信複方產品的持續開發工作具有顯著上行潛力,並進一步呼應我們先前所述加速關鍵研究計畫的意圖,我很高興告知各位,Biovail 已啟動 BVF 146 的第三期臨床試驗;BVF 146 為每日一次的複方產品,由鹽酸 Tramadol 與一種未揭露的非類固醇抗發炎藥(NSAID)所組成。我們相信 BVF 146 可為醫師與醫療照護人員提供一項新型治療選擇,用於中度至中重度慢性疼痛患者。

  • Biovail further believes that BVF 146 may provide physicians with a single tablet option that incorporates two separate classes of drugs, essentially acting analgesic, Tramadol, with an antiinflammatory agent which in turn provides a double pronged, essentially synergistic approach to the management of pain and inflammation. The Phase III clinical trial program will compare BVF 146 to Tramadol alone, the onset alone and to placebo in varying dosage strengths. They will involve several multicenter randomized double blind efficacy studies to measure the effectiveness and safety of BVF 146 for the management of pain and inflammation. We expect this program will be completed to allow an NDA filing in the third quarter of 2008.

    Biovail 進一步認為,BVF 146 可為醫師提供單一錠劑的選擇,將兩種不同類別的藥物納入其中:具鎮痛作用的 Tramadol 與抗發炎藥物,從而以雙管齊下、基本上具協同效應的方式管理疼痛與發炎。第三期臨床試驗計畫將以不同劑量強度比較 BVF 146 與單用 Tramadol、單用(onset)以及安慰劑。試驗將包含多項多中心、隨機、雙盲的療效研究,以衡量 BVF 146 在疼痛與發炎管理上的有效性與安全性。我們預期該計畫將完成並可於 2008 年第三季提交 NDA。

  • Let me now provide you with an update pertaining to two other previously discussed products under development. BVF 012, our enhanced absorption formulation of Venlafaxine actively demonstrates the capacities of our various platform technologies. Thus, not only has Biovail been able to develop a robust once daily bio equivalent formulation that uses significantly less drug to produce the same serum levels, the BVF 012 is also resistant to the effects of alcohol and does not dose dump. We also continue to move forward with our development efforts to treat cardiovascular and metabolic disorders. For example, BVF 211, our controlled release product has received an IND to allow commencement at the clinical program.

    接下來我將就另外兩項先前討論過、仍在開發中的產品提供最新進度。BVF 012 為我們提升吸收的 Venlafaxine 配方,清楚展現我們各項平台技術的能力。因此,Biovail 不僅已能開發出穩健的每日一次生體相等性配方,且使用顯著較少的藥量即可達到相同的血清濃度;BVF 012 亦能抵抗酒精影響,且不會發生劑量傾瀉。我們也持續推進針對心血管與代謝性疾病的開發工作。例如,我們的控釋產品 BVF 211 已取得 IND,得以開始臨床計畫。

  • Biovail is actively involved in discussions with interested parties about the product. As Doug has previously mentioned, in addition to the five products I've discussed, we have an active R&D portfolio. We are now in the process of completing a comprehensive review of our pipeline that results in moving some programs forward, canceling others, as well as initiating some new ones, expect to be able to provide updates pertaining to this initiative and our R&D program in general in the coming months. Doug?

    Biovail 正積極與對該產品有興趣的各方進行討論。正如 Doug 先前提到的,除了我已討論的五項產品之外,我們還擁有一個活躍的研發(R&D)產品組合。我們目前正在完成對研發管線的全面檢視,結果將包括推進部分專案、取消其他專案,以及啟動一些新專案;預期在未來幾個月內,能就此項計畫以及我們整體研發計畫提供最新進展。Doug?

  • - CEO

    - CEO

  • Thank you very much, Peter. In late February, Biovail and marketing partner Ortho-McNeil launched Ultram ER, the first once daily extended release formulation Tramadol to receive approval in the United States. Biovail and OMI continue to believe that Ultram ER is well positioned on the pain ladder between nonsteroidal anti-inflammatory drugs and the Hydrocodone products. To accelerate awareness for the enhanced therapeutic benefits for Ultram ER for patients who may derive the most benefit from it, OMI has made a significant investment in the awareness and promotional activities associated with this drug. These activities include a direct-to-consumer advertising campaign which was launched in late October, the launch of a website which is by the way worldwide web paininformationcenter.com, whose purpose is to educate people with respect to chronic pain and it's treatment. This site, which was launched on October 23, received more than 10,000 hits in it's first week. Biovail and OMI have been very encouraged by the high number of requests from visitors for additional information.

    非常感謝你,Peter。在二月底,Biovail 與行銷合作夥伴 Ortho-McNeil 推出 Ultram ER,這是首個在美國獲准的每日一次緩釋型 Tramadol(曲馬多)製劑。Biovail 與 OMI 仍然相信,Ultram ER 在止痛階梯中,介於非類固醇抗發炎藥(NSAIDs)與 Hydrocodone(氫可酮)產品之間,具備良好定位。為加速提升對 Ultram ER 強化治療效益的認知、並觸及可能從中獲益最大的患者,OMI 已在與該藥相關的認知推廣與促銷活動上投入可觀資金。這些活動包括於十月底啟動的直接面向消費者(DTC)廣告活動,以及網站的上線;順帶一提,網址是 worldwide web paininformationcenter.com,其目的在於教育大眾了解慢性疼痛及其治療。該網站於 10 月 23 日上線,第一週即獲得超過 10,000 次點擊。Biovail 與 OMI 對於訪客提出大量索取更多資訊的需求感到非常鼓舞。

  • Discount cards for Ultram ER, equivalence of the difference in patient out of pocket cost between tier three and tier two formulary positions are are available on another website, worldwide web, Ultram-ER.Com. These discounts allow patients to Eso if Ultram ER is an appropriate treatment for them at a reduced out of pocket cost. Increases to the sample size of Ultram ER which will help healthcare practitioners and their patients with dose titration, and in turn, more effectively get their patients to the appropriate dose.

    Ultram ER 的折扣卡(相當於患者自付費用在處方集第三級與第二級給付層級之間差額)可在另一個網站取得,worldwide web,Ultram-ER.Com。這些折扣讓患者能以較低的自付費用,評估 Ultram ER 是否為適合他們的治療選項。同時也會增加 Ultram ER 的試用品(sample)數量,以協助醫療照護專業人員及其患者進行劑量滴定,進而更有效地讓患者達到適當劑量。

  • And lastly, Biovail and OMI are finalizing an agreement to collectively make a significant additional investment to further create awareness for the brand among those who will benefit from it. Each company will invest an equal amount to further increase the already significant advertising and promotion spending to support Ultram ER.

    最後,Biovail 與 OMI 正在敲定一項協議,將共同再投入一筆可觀的額外資金,以進一步在可從中受益的人群中提升品牌認知。兩家公司將各自投入相同金額,進一步提高目前已相當可觀的廣告與促銷支出,以支持 Ultram ER。

  • Now let me take a few minutes to briefly recap some of the commercial highlights from the first quarter. Wellbutrin XL continues to strengthen it's position in the United States antidepressant market. Total prescriptions for Wellbutrin XL increased 16.4% in the third quarter of 2006 compared with three months ending September 30, 2005. For the first nine months of 2006, total prescriptions for Wellbutrin XL were up 17% compared with the corresponding period in 2005. Indicative of Wellbutrin XL's continually growing market acceptance is that in September this year, Wellbutrin XL captured almost 60% of new prescriptions written for the Wellbutrin brand including Generics. We also continue to work closely with our marketing partner, GlaxoSmithKline as Glaxo continues to proactively move forward with plans to build additional new markets for Wellbutrin XL in Europe.

    接下來我用幾分鐘簡要回顧第一季的一些商業亮點。Wellbutrin XL 持續鞏固其在美國抗憂鬱藥市場的地位。2006 年第三季 Wellbutrin XL 的總處方量較截至 2005 年 9 月 30 日的三個月期間增加 16.4%。2006 年前九個月,Wellbutrin XL 的總處方量較 2005 年同期增加 17%。顯示 Wellbutrin XL 市場接受度持續提升的是:今年 9 月,Wellbutrin XL 幾乎拿下 Wellbutrin 品牌(含學名藥)所有新開立處方的 60%。我們也持續與行銷合作夥伴葛蘭素史克(GlaxoSmithKline)密切合作,因為 Glaxo 正積極推進在歐洲為 Wellbutrin XL 開拓更多新市場的計畫。

  • Biovail Zovirax franchise continues to fortify it's position as the dominant treatment in the topical herpes market Zovirax continued to strengthen it's market position in the third quarter. Zovirax cream and Zovirax Ointment captured a combined 72.9% of the topical antiviral market for herpes up 5.2 percentage points from the corresponding period in 2005. Total prescriptions for Cardizem LA, decreased 3.1% in the third quarter of 2006 compared with the corresponding three-month period in 2005. This can largely be attributed to a manufacturing issue that has impacted Biovail's ability to supply the lower dosage strengths of 120 milligram and 180 milligram strengths of Cardizem LA to our marketing partner, Kos Pharmaceuticals. We firmly believe this issue will be resolved and that trade supplies will return to normal levels in December of this year.

    Biovail 的 Zovirax 產品線持續鞏固其在外用疱疹市場作為主導治療的地位,Zovirax 在第三季也持續強化其市場地位。Zovirax 乳膏與 Zovirax 軟膏合計取得外用抗病毒疱疹市場 72.9% 的市占率,較 2005 年同期提高 5.2 個百分點。Cardizem LA 的總處方量在 2006 年第三季較 2005 年同期三個月期間下降 3.1%。這主要歸因於一項製造問題,影響了 Biovail 向行銷合作夥伴 Kos Pharmaceuticals 供應 Cardizem LA 低劑量規格(120 毫克與 180 毫克)的能力。我們堅信此問題將會解決,且通路供貨將於今年 12 月恢復至正常水準。

  • The performance of biovail pharmaceutical Canada continues to be negatively impacted by the genericization of Tiazac and Wellbutrin SR. Total prescriptions for BPC were down 25% and 30% respectively for the third quarter and first nine months of 2006 versus the corresponding periods in 2005. However, we're very pleased with the continuing growing acceptance of Tiazac XE which was launched in January 2005. Prescriptions were up 127% in the third quarter of 2006 and 271% year-to-date compared to the corresponding periods for 2005. In April 2006, BPC launched Wellbutrin XL to Canadian physicians, however we're still in the early phase of the launch, we are very encouraged by early prescription trends. As of September 30, 2006, Wellbutrin XL captured about 14% of Bupropion prescriptions.

    Biovail Pharmaceutical Canada(BPC)的表現持續受到 Tiazac 與 Wellbutrin SR 學名藥化的負面影響。BPC 的總處方量在 2006 年第三季及前九個月,分別較 2005 年同期下降 25% 與 30%。然而,我們對於 2005 年 1 月推出的 Tiazac XE 持續獲得日益提升的市場接受度感到非常滿意。其處方量在 2006 年第三季較 2005 年同期增加 127%,年初至今較 2005 年同期增加 271%。2006 年 4 月,BPC 向加拿大醫師推出 Wellbutrin XL;不過我們仍處於上市初期階段,但早期處方趨勢令我們非常鼓舞。截至 2006 年 9 月 30 日,Wellbutrin XL 約占 Bupropion(安非他酮)處方的 14%。

  • I would also like to point out that private and public formularies continue to respond favorably to Wellbutrin XL. In the past six months Biovail has secured formulary coverage with all major Canadian private health insurers. In addition, five of ten provincial government formularies representing in excess of 60% of Bupropion's government r claims now reimburse Wellbutrin XL and we expect formulary decisions from other provincial governments over the next two quarters. Ken, this concludes my remarks.

    我也想指出,私人與公立處方集(formulary)對 Wellbutrin XL 的反應仍然正面。在過去六個月,Biovail 已取得所有主要加拿大私人健康保險公司的處方集給付涵蓋。此外,十個省級政府處方集中已有五個(代表超過 60% 的 Bupropion 政府理賠)目前已給付 Wellbutrin XL;我們預期在接下來兩個季度,將收到其他省政府的處方集決策。Ken,我的發言到此結束。

  • - SVP-Fin., Corp. Affairs

    - SVP-Fin., Corp. Affairs

  • Thank you, Doug. I would now like to ask Charles Rowland, Biovail's Senior Vice President and Chief Financial Officer, to provide additional information on the Company's financial performance for the third quarter and first nine months of 2006. Charlie?

    謝謝你,Doug。接下來我想請 Biovail 資深副總裁兼財務長 Charles Rowland,就公司 2006 年第三季及前九個月的財務表現提供更多資訊。Charlie?

  • - SVP, CFO

    - SVP, CFO

  • Thanks, Ken. Good morning, everyone. Biovail reports it's financial results in U.S. dollars and under U.S. Generally Accepted Accounting Principles or U.S. GAAP. All earnings per share information discussed in the conference call today will be presented on a diluted basis.

    謝謝,Ken。各位早安。Biovail 以美元編製並報告其財務結果,並依據美國一般公認會計原則(Generally Accepted Accounting Principles),亦即美國 GAAP。今天電話會議中討論的所有每股盈餘資訊,將以稀釋後基礎呈列。

  • On a consolidated basis total revenues for the three months ended September 30, 2006, were were 289.6 million compared with with 258.1 million for the third quarter of 2005, an increase of 12%. Total revenues for the first three quarters of 2006 were 762.9 million up 18% from the the 647.9 million for the corresponding period in 2005. These revenues represent record levels of performance for the Company.

    以合併基礎計算,截至 2006 年 9 月 30 日止三個月的總營收為 289.6 百萬,相較 2005 年第三季的 258.1 百萬,增加 12%。2006 年前三季總營收為 762.9 百萬,較 2005 年同期的 647.9 百萬增加 18%。這些營收代表公司創紀錄的業績水準。

  • Third quarter 2006 net income was a net loss of of 56.5 million compared with net income of of 101.7 million for the corresponding 2005 period. For the nine months ended September 30, 2006, net income was 88.6 million compared with 116.5 million for the same period a year earlier. In the third quarter, Biovail reported a net loss per share of $0.35 versus earnings per share of $0.64 for the third quarter of 2005. In the first nine months of 2006, EPS was $0.55 compared with $0.73 for the first nine months of 2005. GAAP net income and GAAP EPS figures for the third quarter of 2006 were negatively impacted by $147 million non-cash write down of intangible assets, a $40 million charge related to the contract loss contingency in the Wellbutrin XL agreement with GSK, and a $6.8 million charge related to the loss profit provision in the Company's agreement with Kos related to Cardizem LA. These charges were partially offset by a 4 million gain related to the termination of the Athpharma agreement. These charges negatively impacted net income and EPS in the third quarter of 2006 by 189.8 million and $1.18 respectively.

    2006 年第三季淨利為淨虧損 5,650 萬,相較於 2005 年同期淨利 1 億 170 萬。截至 2006 年 9 月 30 日止九個月,淨利為 8,860 萬,相較於前一年同期的 1 億 1,650 萬。第三季,Biovail 每股淨虧損為 0.35 美元,而 2005 年第三季每股盈餘為 0.64 美元。2006 年前九個月每股盈餘(EPS)為 0.55 美元,較 2005 年前九個月的 0.73 美元為低。2006 年第三季的 GAAP 淨利與 GAAP EPS 數據受到以下因素負面影響:無現金無形資產減損 1.47 億美元、與 GSK 之 Wellbutrin XL 協議中合約損失或有事項相關之 4,000 萬美元費用,以及與 Kos 就 Cardizem LA 之協議中損失利潤條款相關之 680 萬美元費用。上述費用部分由與終止 Athpharma 協議相關之 400 萬美元收益所抵銷。上述費用使 2006 年第三季淨利與 EPS 分別減少 1 億 8,980 萬與 1.18 美元。

  • GAAP net income and EPS figures for the third quarter of 2005 were negatively impacted ed by 1.1 million and $0.01 respectively. As a result of the restructuring charge related to the May 2005 realignment of Biovail's U.S. commercial operations. GAAP net income and EPS figures for the first nine months of 2006 were also impacted by initial $4.5 million provision related to the contract loss contingency and the GSK agreement recorded in the second quarter of 2006. In aggregate, these items negatively impacted net income and EPS in the first nine months of 2006 by 194.3 million or $1.21 respectively. Net income and EPS for the first nine months of 2005 were negatively impacted in the amount of of 51.1 million and $0.32. As a result of the restructuring charge, a non-cash write down of assets, and the write-off of inventory related to the transaction with Kos in May of 2005.

    2005 年第三季的 GAAP 淨利與 EPS 數據亦分別受到 110 萬與 0.01 美元的負面影響。此係因 2005 年 5 月 Biovail 美國商業營運重整所產生之重組費用所致。2006 年前九個月的 GAAP 淨利與 EPS 數據亦受到影響,原因為 2006 年第二季入帳、與合約損失或有事項及 GSK 協議相關之初始 450 萬美元準備。合計而言,這些項目使 2006 年前九個月的淨利與 EPS 分別減少 1 億 9,430 萬或 1.21 美元。2005 年前九個月的淨利與 EPS 分別受到 5,110 萬與 0.32 美元的負面影響。此係因重組費用、資產之無現金減損,以及與 2005 年 5 月與 Kos 交易相關之存貨沖銷所致。

  • For a reconciliation of EPS, excluding specific items to GAAP EPS, see the table included in our earnings news release. We encourage investors to examine the reconciling adjustments between GAAP and non-GAAP measurements contained in the news release.

    關於排除特定項目之 EPS 與 GAAP EPS 的調節,請參閱我們盈餘新聞稿中所附之表格。我們鼓勵投資人檢視新聞稿中所載 GAAP 與非 GAAP 衡量指標之間的調節調整項目。

  • Adjusting for these specific non-cash items, Biovail posted record net income, excluding specific items in the third quarter of of 133.3 million and earnings per share excluding specific items of $0.83. Adjusting for these one-time non-cash items Biovail posted record net income for the nine months ended September 30, 2006, of 282.9 million and earnings per share of $1.77. Biovail's portfolio of products continues to perform strongly in the third quarter of 2006. Product revenues for the three months ended September 30, 2006, were 277.3 million, compared with 244.5 million in the third quarter of 2005, an increase of 13%. Product revenues for the nine months ended September 30, 2006, were up 19% to 728 million compared with 609.5 million for the nine months ended September 30, 2005. These results were driven by Wellbutrin XL, Zovirax and the Company's portfolio of Legacy products which were partially offset by declines for DTC and our generics portfolio.

    若就上述特定無現金項目進行調整,Biovail 於 2006 年第三季(排除特定項目)創下紀錄之淨利 1 億 3,330 萬,且排除特定項目之每股盈餘為 0.83 美元。若就上述一次性無現金項目進行調整,Biovail 截至 2006 年 9 月 30 日止九個月創下紀錄之淨利為 2 億 8,290 萬,每股盈餘為 1.77 美元。Biovail 的產品組合於 2006 年第三季持續展現強勁表現。截至 2006 年 9 月 30 日止三個月之產品營收為 2 億 7,730 萬,相較於 2005 年第三季的 2 億 4,450 萬,成長 13%。截至 2006 年 9 月 30 日止九個月之產品營收較截至 2005 年 9 月 30 日止九個月的 6 億 950 萬成長 19% 至 7 億 2,800 萬。上述結果主要由 Wellbutrin XL、Zovirax 及本公司之 Legacy 產品組合所帶動,但部分被 DTC 與我們學名藥產品組合之下滑所抵銷。

  • Wellbutrin XL revenues were were 123.3 million in the third quarter of 2006 compared with 109.3 million for the same period a year ago, an increase of 13%, for the nine month period ended September 30, 2006, Wellbutrin XL generated revenues of of 302.2 million, 40% higher than the the 216.5 million for the same period in 2005. Wellbutrin XL's performance in the third quarter can be attributed to GSK's efforts to drive prescription growth combined with price increases implemented by GSK. Biovail also entered the third tier of our three tier supply agreement during this quarter. Revenues for the third quarter of 2006 for Biovail Zovirax franchise were up 22% to 27.8 million compared with 22.8 million in the prior year period. For the nine month period ended September 30, 2006, Zovirax generated 81.3 million in revenue, a 19% increase over the $68.2 million in the corresponding period in 2005. This performance was driven by price growth and the impact of our distribution service agreements in reducing our actual returns experience.

    Wellbutrin XL 於 2006 年第三季營收為 1 億 2,330 萬,較前一年同期的 1 億 930 萬成長 13%;截至 2006 年 9 月 30 日止九個月,Wellbutrin XL 產生營收 3 億 220 萬,較 2005 年同期的 2 億 1,650 萬高出 40%。Wellbutrin XL 於第三季之表現可歸因於 GSK 推動處方成長之努力,以及 GSK 所實施之價格調升。本季 Biovail 亦進入我們三層供應協議之第三層級。2006 年第三季 Biovail Zovirax 系列營收較前一年同期成長 22% 至 2,780 萬(前一年同期為 2,280 萬)。截至 2006 年 9 月 30 日止九個月,Zovirax 產生營收 8,130 萬,較 2005 年同期的 6,820 萬成長 19%。此表現主要由價格成長,以及我們的配送服務協議在降低實際退貨經驗方面之影響所帶動。

  • In the third quarter of 2006, Biovail pharmaceutical Canada generated revenues of 13.7 million compared with 23.5 million in 2005. BPC revenues for the first nine months of 2006 were 53 million compared with 72.1 million for the corresponding period a year earlier. These declines can be mainly attributed to the recent entry of generic competitors for Tiazac and Wellbutrin SR. In the third quarter of 2006 Cardizem LA generated revenue of 21.5 million compared with 17.3 million for the corresponding period in 2005. The increase reflects a 7.2 million positive cumulative adjustment related to price increases affected by Kos since May 2005 as well as a 6.5 million back order situation that remained for Cardizem LA at the end of the third quarter of 2006. In the first nine months of 2006 Cardizem LA generated revenue of 46.9 million compared with 46.3 million in the first nine months of 2005. The amortization of deferred revenues associated with the May 2005 Kos transaction positively impacted Cardizem LA revenues by 3.8 million and 11.3 million in the third quarter and first nine months of 2006 respectively. This compares with 3.8 million and 6.3 million for the corresponding periods a year earlier.

    2006 年第三季,Biovail Pharmaceutical Canada 之營收為 1,370 萬,較 2005 年的 2,350 萬為低。2006 年前九個月 BPC 營收為 5,300 萬,較前一年同期的 7,210 萬為低。上述下滑主要可歸因於 Tiazac 與 Wellbutrin SR 近期有學名藥競爭者進入市場。2006 年第三季 Cardizem LA 產生營收 2,150 萬,較 2005 年同期的 1,730 萬增加。此增幅反映自 2005 年 5 月起 Kos 調漲價格所致之 720 萬正向累積調整,以及截至 2006 年第三季末 Cardizem LA 仍存在之 650 萬缺貨(back order)情況。2006 年前九個月 Cardizem LA 產生營收 4,690 萬,較 2005 年前九個月的 4,630 萬略增。與 2005 年 5 月 Kos 交易相關之遞延營收攤銷,分別於 2006 年第三季與前九個月對 Cardizem LA 營收帶來 380 萬與 1,130 萬之正面影響。相較之下,前一年同期分別為 380 萬與 630 萬。

  • Also, as a result of manufacturing issues that have halted production of the lower strengths, the 120 and 180 milligram of Cardizem LA, Biovail recorded a $6.8 million charge related to lost profits based on contractual provisions in the agreement with Kos. Biovail does anticipate a return to full production of these strengths in December of 2006. Ultram ER generated 18.6 million in revenues in the third quarter of 2006. Product sales in the first nine months of the year were 34.6 million which is a net -- which is net of a 7.8 million return provision related to the decisions by Biovail and partner Ortho-McNeil to issue a level two recall of certain dosages of the product from the market. Revenues for Biovail's portfolio of Legacy products were up 31% to 38.7 million in the third quarter of 2006 versus 29.5 million for the comparable period in 2005.

    此外,由於製造問題導致 Cardizem LA 低劑量規格(120 與 180 毫克)停產,Biovail 依據與 Kos 協議中的合約條款,就損失利潤認列 680 萬美元費用。Biovail 預期於 2006 年 12 月恢復上述規格之全面生產。Ultram ER 於 2006 年第三季產生營收 1,860 萬。本年度前九個月之產品銷售為 3,460 萬,該金額為淨額——已扣除 780 萬退貨準備,此退貨準備係因 Biovail 與合作夥伴 Ortho-McNeil 決定就該產品部分劑量自市場發出第二級召回(level two recall)所致。Biovail 之 Legacy 產品組合於 2006 年第三季營收成長 31% 至 3,870 萬,而 2005 年同期為 2,950 萬。

  • For the first nine months of 2006, revenues for Biovail's off patent branded pharmaceutical products were up 13% to 110.9 million compared with 98.4 million in 2005. These increases can be attributed to higher sales of Cardizem CD and branded and generic Tiazac. Gross margins based on product sales were 79 and 77% in the third quarter and first nine months of 2006 compared with 79 and 75% in the corresponding periods in 2005. Gross margins in 2006 were favorably impacted by price increases and partially -- these were partially offset by costs associated with recent manufacturing issues.

    2006年前九個月,Biovail 已過專利期之品牌藥品產品的營收較2005年的9,840萬增加13%至1.109億。這些增長可歸因於 Cardizem CD 以及品牌與學名 Tiazac 的銷售增加。以產品銷售計算的毛利率在2006年第三季及前九個月分別為79%與77%,相較於2005年同期的79%與75%。2006年的毛利率受惠於提價而有所改善,並且部分——這些改善部分被近期製造問題相關成本所抵銷。

  • Turning now to expenses. SG&A for the third quarter of 2006 were 50.2 million compared with 42.4 million in the third quarter of 2005. This increase reflects the inclusion of stock based compensation and higher legal expenses primarily driven by our intellectual property litigation. For the first nine months of the year, SG&A was 173.4 million compared with 174.3 million for the corresponding period a year earlier. The modest decrease reflects the May 2005 restructuring of the Company's U.S. commercial operation which was largely offset by the costs related to the Ultram ER recall to best of our intellectual properties, Sarbanes-Oxley compliance, information technology infrastructure upgrade, the launches of Glumetza and Wellbutrin XL in Canada, and the inclusion of stock based compensation expenses.

    接下來談費用。2006年第三季的銷售、一般及行政費用(SG&A)為5,020萬,較2005年第三季的4,240萬增加。此增幅反映納入以股票為基礎的薪酬,以及主要由智慧財產權訴訟所帶動的較高法律費用。今年前九個月,SG&A為1.734億,較一年前同期的1.743億略低。這項小幅下降反映公司於2005年5月對美國商業營運進行重整;但該效益大多被與 Ultram ER 召回相關的成本、我們在智慧財產權方面的最佳努力、沙賓法案(Sarbanes-Oxley)遵循、資訊科技基礎設施升級、在加拿大推出 Glumetza 與 Wellbutrin XL,以及納入以股票為基礎的薪酬費用所抵銷。

  • As Doug mentioned earlier, Biovail's management team continues to carefully review our cost structure. This ongoing effort has resulted in a reduction in SG&A spending which we expect to continue for the rest of the year. Research and development expenditures were 26.4 million for the third quarter of 2006 and 67.1 million for the first nine months of 2006 compared with 19.9 million and 62.1 million for the corresponding periods in 2005 respectively. These spending levels reflect the timing of the initiation of various clinical programs including Phase III trials for BVF 146 and an increase in activity related to several high value development programs including the submission of an NDA for BVF 033, a new Bupropion sales.

    如Doug先前提到,Biovail管理團隊持續審慎檢視我們的成本結構。這項持續性的努力已使SG&A支出下降,我們預期此趨勢將在今年剩餘期間延續。2006年第三季研發支出為2,640萬,2006年前九個月為6,710萬,分別高於2005年同期的1,990萬與6,210萬。這些支出水準反映多項臨床計畫啟動時點的影響,包括BVF 146的第三期試驗,以及與數個高價值開發計畫相關活動增加,其中包括提交BVF 033的新藥申請(NDA),以及一項新的安非他酮(Bupropion)銷售。

  • With regard to the balance sheet, at September 30, 2006, Biovail had cash balances in excess of of 625 million. The Company's long term debt to equity ratio stood at 0.3 at the end of the third quarter of 2006 compared to 0.4 at December 31, 2005. Cash flows from operations were 81.4 million in the third quarter of 2006 compared with 122.4 million in the corresponding period in 2005. Net capital expenditures in the third quarter of 2006 amounted to 6.5 million compared with 12.9 million in the third quarter of 2005. This decrease reflects the completion of the expansion of Biovail's manufacturing facility in Ziabac, Manitoba. Biovail is continuing it's dividend policy. The Company will pay a dividend of $0.125 per share payable on November 30, 2006, for shareholders of record on November 22, 2006.

    就資產負債表而言,截至2006年9月30日,Biovail的現金餘額超過6.25億。公司長期負債對股東權益比率於2006年第三季末為0.3,較2005年12月31日的0.4下降。2006年第三季營運活動現金流量為8,140萬,較2005年同期的1.224億減少。2006年第三季淨資本支出為650萬,較2005年第三季的1,290萬下降。此下降反映Biovail位於曼尼托巴省Ziabac的製造設施擴建已完成。Biovail將持續其股利政策。公司將支付每股0.125美元股利,於2006年11月30日發放,股權登記日為2006年11月22日。

  • Turning now to financial guidance for the rest of 2006, as a result of this stronger than anticipated third quarter results, Biovail is increasing it's 2006 diluted EPS guidance excluding specific items to a range of $2.50 to $2.60 from a previous range of $2.30 to $2.40. In addition, Biovail is increasing it's 2006 cash flow from operations guidance to a range of of 460 million to 480 million from a range of of 400 million to 460 million. Biovail's 2006 financial guidance assumes that a generic formulation of Wellbutrin XL will not be launched in 2006 and as before, Biovail's financial guidance does not include the impact of new generic competition for any of the Company 's key products, any business development activities, any new supply and distribution agreements or acquisitions, restructuring or other specific charges.

    接下來談2006年剩餘期間的財務指引。由於第三季業績強於預期,Biovail將2006年(排除特定項目)的稀釋每股盈餘(EPS)指引由先前的2.30至2.40美元上調至2.50至2.60美元區間。此外,Biovail將2006年營運活動現金流量指引由4.00億至4.60億上調至4.60億至4.80億區間。Biovail的2006年財務指引假設Wellbutrin XL的學名藥配方不會在2006年上市;且如同先前,Biovail的財務指引不包含公司任何主要產品新增學名藥競爭的影響、任何業務開發活動、任何新的供應與經銷協議或併購、重整或其他特定費用。

  • For more comprehensive information pertaining to Biovail's financial and operational performance for the third quarter and first nine months of 2006, please refer to the news release distributed earlier this morning. That concludes my review of Biovail's financial performance. Ken?

    如需更完整了解Biovail於2006年第三季及前九個月的財務與營運表現,請參閱今晨稍早發布的新聞稿。以上為我對Biovail財務表現的回顧。Ken?

  • - SVP-Fin., Corp. Affairs

    - SVP-Fin., Corp. Affairs

  • Thanks very much, Charlie. I would now like to call on Doug Squires to make his closing remarks. Doug?

    非常感謝你,Charlie。接下來我想請Doug Squires做結語。Doug?

  • - CEO

    - CEO

  • Thanks, Ken. In closing, let me reiterate that Biovail is a very strong Company. The value of the Company's business model is significant. It has resulted in excellent profitability and generates robust cash flow. We expect this to be the case even after the entry of generic versions of Wellbutrin XL whenever that may be.

    謝謝,Ken。最後,我想再次強調,Biovail是一家非常強健的公司。公司的商業模式價值重大。這帶來了優異的獲利能力並產生強勁的現金流。我們預期即使在Wellbutrin XL的學名藥版本於未來某個時間點進入市場之後,情況仍將如此。

  • As I've discussed previously, Biovail's executive team will implement a number of initiatives to significantly reduce operating costs and improve operating efficiencies without sacrificing our committment to our key development programs. Research and development has been and will continue to be the major growth engine for Biovail. We will continue to invest in R&D to ensure we can further leverage our value creating drug delivery technologies. This in turn will enable us to realize our short-term and long term business objectives and to maximize shareholder value.

    如我先前所述,Biovail的高階管理團隊將推動多項措施,在不犧牲我們對關鍵開發計畫承諾的前提下,大幅降低營運成本並提升營運效率。研發一直是、也將持續是Biovail最主要的成長引擎。我們將持續投資研發,以確保能進一步運用我們創造價值的藥物傳輸技術。這將使我們得以達成短期與長期的業務目標,並將股東價值最大化。

  • This concludes my comments this morning and the formal portion of today's call. I will now turn the call over to the conference operator for questions. Operator?

    以上為我今天上午的評論,以及今日電話會議的正式部分。接下來我將把電話交給會議接線員進行提問。接線員?

  • Operator

    Operator

  • Thank you, sir. [OPERATOR INSTRUCTIONS] Our first question is from Doug Miehm of RBC Capital Markets. Please go ahead.

    謝謝您,先生。[接線員指示] 我們的第一個問題來自RBC Capital Markets的Doug Miehm。請開始。

  • - Analyst

    - Analyst

  • Thank you, and good morning. Just a couple questions and first ones a housekeeping one with respect to Ultram ER. Could you tell me what the pipeline fill was for the quarter given that you did have the recall in Q2 tipped to the 17.6 that you put up?

    謝謝,早安。我有幾個問題,第一個是關於Ultram ER的例行性問題。鑑於你們在第二季進行了召回,能否告訴我本季的通路補貨(pipeline fill)是多少,對應到你們公布的1,760萬?

  • - CEO

    - CEO

  • Actually, off the top of my head I don't think I can do that, Doug, but we'll get that information for you and get it to you before the call.

    老實說,我現在一時之間可能無法回答,Doug,但我們會把那個資訊整理給你,並在電話會議結束前提供給你。

  • - Analyst

    - Analyst

  • Okay, great. In terms of SG&A, it was significant decrease from what we saw in Q2. I'm wondering if you can give me a bit more clarity on why it's actually lower and what the outlook could be given the changes you're expected to make over the next year or two.

    好的,很好。就SG&A而言,較我們在第二季看到的水準顯著下降。我想請你更清楚說明為何實際上更低,以及考量你們預期在未來一到兩年要做的變動,後續展望可能如何。

  • - CEO

    - CEO

  • Yes, I'm not going to be too specific as it relates to the next year or two, Doug, because this is really not the time to talk about that until we finalize that, but the reason that the sort of the run rate of current G&A expenses is lower is not accidental. It's as a result of being very prudent on what we spend as a result of what happened in the California Court in early August, so as an example of that, we did not restrain our R&D expenditures. We looked everywhere else, even just looking at '06 expenditures to make sure that we weren't adding people that would not be bringing near term value and might be longer term people that we could either delay or delay some programs, into '07 or even beyond that were critical to the success of the business, and that really is what's impacted the current G&A run rate.

    是的,Doug,關於未來一到兩年我不會講得太具體,因為在我們定案之前,現在並不是談這個的時機;但目前一般及行政(G&A)費用的經常性水準較低並非偶然。這是因為在八月初加州法院事件之後,我們對支出採取非常審慎的態度;舉例來說,我們並沒有限制研發支出。我們檢視了其他所有地方,甚至只看2006年的支出,以確保我們沒有增加那些無法帶來近期價值的人力;對於可能屬於較長期的人力,我們可以延後,或將某些對業務成功至關重要的計畫延到2007年甚至更晚,而這正是影響目前G&A經常性支出水準的原因。

  • It's things like doing some real reviews on hiring people, new people, making sure that it's looking at replacements, and who does what, and so on. So that's an ongoing operational process. Charlie you wanted to say something?

    像是對招募人員、新進人員進行一些真正的審查,確保會檢視替補人選、誰負責什麼等等。所以那是一個持續進行的營運流程。Charlie,你想說些什麼嗎?

  • - SVP, CFO

    - SVP, CFO

  • Doug, and there's a couple of other things too. A lot of our investments for Sarbanes-Oxley compliance and upgrading our infrastructure in IT and so fourth really all happened in the first half of the year, so that higher rate of spend is behind us.

    Doug,另外還有幾件事。我們為了符合《沙賓法案》(Sarbanes-Oxley)以及升級我們的 IT 基礎設施等等所做的大部分投資,其實都發生在上半年,所以較高的支出速度已經過去了。

  • - Analyst

    - Analyst

  • Okay, great. And then just finally, Doug, just strategic initiatives, you've got got $625 million in the bank plus your lines available. When might we hear a bit more about this and what you might do with how you're going to reinvest or deploy those cash assets? Thank you.

    好的,很好。最後,Doug,關於策略性計畫,你們帳上有 6.25 億美元現金,另外還有可動用的授信額度。我們何時能再多聽一些你們對此的想法,以及你們打算如何再投資或配置這些現金資產?謝謝。

  • - CEO

    - CEO

  • Sure. We've gone back to this question a number of times over the call. We have a very active business development organization looking at a variety of opportunities and a variety of areas whether they're technologies or products for Canada and so on as I've described before. And we will announce those, in fact, as they happen in the coming months. I would just make an observation, however, one of the interesting observations that we've made in the past years for some of the areas that we look at, the valuations are extremely high, and we're -- I wouldn't say we're conservative but we're certainly not going to be over the top in anything that we acquire or any deal that we do.

    當然。我們在這通電話中已多次回到這個問題。我們有一個非常積極的業務開發組織,正如我先前所描述的,正在不同領域、不同機會上評估各種可能性,不論是技術或產品(例如加拿大等市場)。而且我們會在未來幾個月內,隨著事情發生就對外宣布。不過我想補充一點觀察:過去幾年我們在某些關注領域看到的估值非常高;我們——我不會說我們保守,但我們肯定不會在任何收購或任何交易上做得過頭。

  • Operator

    Operator

  • Thank you. The following question is from Marc Goodman of Credit Suisse. Please go ahead.

    謝謝。下一個問題來自 Credit Suisse 的 Marc Goodman。請開始。

  • - Analyst

    - Analyst

  • I have a couple of questions. I guess first one is on the dividend. My understanding is that you put the dividend in place when you thought you were going to do this Legacy spin and that was temporary. I mean, can you comment on the dividend and how committed you are to the dividend over the next year or two? That's number one.

    我有幾個問題。我想第一個是關於股利。我的理解是,你們在認為會進行 Legacy 分拆時設立了股利,而那是暫時性的。你能否評論一下股利,以及你們對未來一到兩年維持股利的承諾程度?這是第一個。

  • Number two, I don't understand why you have to put more marketing dollars into Ultram ER. I mean, as part of this deal, gave J&J a late stage product and I'm just kind of wondering why is J&J just not spending their own money? That's what I was to understand that this deal was and you get a royalty.

    第二個,我不太理解為什麼你們還需要在 Ultram ER 上投入更多行銷費用。我的意思是,作為這筆交易的一部分,你們把一個後期產品交給了 J&J,我只是想知道為什麼 J&J 不自己花錢?我原本理解這筆交易就是這樣,而你們拿的是權利金。

  • And then my third question has to do with two of the projects that you mentioned in R&D. One is a controlled release carvedilol, obviously Glaxo has a chloride controlled release already on the market and then you mentioned an enhanced absorption Venlafaxine and there's a second gen Venlafaxine on the market, so I guess I'm just wondering what the value is of those two projects, just given what the partner, obvious partner have their own projects, just wondered on that and when are we going to see clinical data on these combinations? I mean I know you got to do superiority versus the individual project -- products so it's very difficult to do that, doesn't matter what kind of product it is, I'm just wondering when will we see data to know that you've got these combos working?

    第三個問題與你們在研發中提到的兩個專案有關。一個是控釋型 carvedilol,顯然葛蘭素史克(Glaxo/GSK)已經有一個控釋產品在市場上;另外你們提到增強吸收的 Venlafaxine,而市場上也有第二代 Venlafaxine,所以我想知道這兩個專案的價值是什麼,尤其考量到合作夥伴——明顯的合作夥伴——也有自己的專案;想請教這點,以及我們何時會看到這些組合的臨床數據?我的意思是,我知道你們必須相對於單一專案——產品——做優效性(superiority)比較,所以這非常難做,不管是什麼類型的產品;我只是想知道我們何時會看到數據,好讓我們知道你們的這些組合確實有效?

  • - CEO

    - CEO

  • Okay. Let me take the first of 18 questions you had there. On dividend, the Board approves the dividend at every quarter and I'm not sure the dividend policy was decided by the Board in the way that you've characterized it as solely an outflow of Legacy. I think it's a reflection of very significant cash flow and an opportunity to return some value to shareholders as that continues. It certainly doesn't inhibit our ability to do anything that we want to do.

    好的。我先回答你那 18 個問題中的第一個。關於股利,董事會每一季都會核准股利;我不確定董事會的股利政策是否如你所描述,僅僅是因為 Legacy 的分拆而決定、且只是資金外流。我認為這反映了非常可觀的現金流,以及在現金流持續的情況下,將部分價值回饋給股東的機會。這當然不會妨礙我們做任何我們想做的事。

  • You made a couple of comments I think on, you had some R&D questions on carvedilol and Venlafaxine. Carvedilol and Venlafaxine have been in our pipeline for quite awhile and of course we're well aware of the entry of the GSK product to the market and that in fact is part of the reason why this has potentially very significant value and there are partners out there that see huge value in this product. The Venlafaxine that we have under development, we think is also potentially highly valuable, not just for it's enhanced absorption characteristics but because it is significantly alcohol resistant and in psychoactive compound, that's not a trivial issue. The FDA is very active in this front and the product that we have is clearly -- does not exceed or result of rapid release in the presence of alcohol.

    你也提到一些研發問題,關於 carvedilol 和 Venlafaxine。Carvedilol 和 Venlafaxine 在我們的產品線中已經有一段時間了,當然我們也很清楚 GSK 產品進入市場;而這其實正是其可能具有非常重大價值的原因之一,市場上也有合作夥伴認為這個產品有巨大的價值。我們正在開發的 Venlafaxine,我們也認為可能具有很高價值,不僅因為其增強吸收特性,還因為它具有顯著的抗酒精破壞(alcohol resistant)特性;對於精神活性化合物而言,這不是小事。FDA 在這方面非常積極,而我們的產品在酒精存在下,明確地——不會超標或導致快速釋放。

  • Data on Phase III programs, we're well aware of the issues of combination trials and combination of rule and so on, how difficult that is and that's one of the reasons why we brought Dr. Peter Silverstone on who has tremendous experience in these areas and knows them for both in pain and in depression, and often the complication and in turn something able to sort differences between the various groups is related to the skill of the investigators and the quality of the trial that's conducted as opposed to the rationale for the combination in the first place, and combinations do get approved and they do very well and we'll show the Phase III data when we have Phase III data to show. Peter did you want to make any additional comments?

    至於第三期(Phase III)計畫的數據,我們很清楚組合試驗、組合規則等等的問題,以及其難度;這也是我們延攬 Peter Silverstone 醫師加入的原因之一,他在這些領域有非常豐富的經驗,無論是在疼痛或憂鬱症方面都很熟悉。很多時候,複雜性、以及能否區分各組差異,與其說取決於一開始的組合邏輯,不如說取決於研究者的技巧與試驗執行的品質;而組合療法確實能獲得核准且表現良好。我們會在有第三期數據可公布時公布第三期數據。Peter,你想補充什麼嗎?

  • - SVP, Medical, Scientific Affairs

    - SVP, Medical, Scientific Affairs

  • No, thank you.

    不用,謝謝。

  • - Analyst

    - Analyst

  • I was just wondering, can you comment on when those Phase III started and when you think they will be done?

    我只是想問,你能否評論一下那些第三期試驗何時開始,以及你認為何時會完成?

  • - SVP, Medical, Scientific Affairs

    - SVP, Medical, Scientific Affairs

  • Well, as I said earlier, the Phase III program has started. I'm not detailing at this time the individual data each of the elements of the Phase III program. The intention is to have an MBA in the third quarter of 2008 and obviously the trials will be done in time to allow that to proceed.

    嗯,正如我先前所說,第三期計畫已經開始。我目前不會細談第三期計畫中各個要素的個別數據。目標是在 2008 年第三季提交 MBA,顯然試驗會在足以支持該進程的時間內完成。

  • - CEO

    - CEO

  • Marc , I'm sorry. I think I missed one question that you had. I'm looking at my list here which was about--.

    Marc,不好意思。我想我漏掉了你的一個問題。我在看我的清單,應該是關於——。

  • - Analyst

    - Analyst

  • Doug you had mentioned that you were going to put money in--.

    Doug,你提到你們會投入資金在——。

  • - CEO

    - CEO

  • Yes, that's the one I was thinking about about Ultram. Now, we look at this relationship with OMI as a partnership. We are very actively involved in discussing what works, what doesn't work. Our companies are all companies, right? They do their budgeting at certain times and as we looked at it, we saw there was an opportunity for us to increase beyond the contractual committment but we're not talking about reducing a contractual committment or supplementing what Ortho-McNeil has committed to. This is over and above the fact. The reason it makes sense sense for Biovail to do that now is that in 2007, we move the upper tier of our supply price which is we go from 27.5% to 37.5% so every additional unit we generate in 2007 is high value.

    對,就是我在想的那個關於 Ultram 的問題。我們把與 OMI 的這段關係視為一種夥伴關係。我們非常積極地參與討論哪些有效、哪些無效。我們的公司都是公司,對吧?他們會在特定時間點編列預算;而我們在檢視後看到一個機會,可以在合約承諾之外再增加投入,但我們不是在談降低合約承諾,也不是在補貼 Ortho-McNeil 已承諾的部分。這是額外的投入。Biovail 現在這麼做之所以合理,是因為在 2007 年,我們會進入供應價格的更高級距,也就是從 27.5% 提升到 37.5%,因此我們在 2007 年每多帶動一個額外單位的銷量,價值都很高。

  • - Analyst

    - Analyst

  • Okay.

    好的。

  • Operator

    Operator

  • The following question is from Christine Charette of BMO Capital Market. Please go ahead

    下一個問題來自 BMO Capital Market 的 Christine Charette。請開始

  • - Analyst

    - Analyst

  • Hi, thank you. You mentioned an R&D review. Could you give us some timing on that? Is it possible to get that before the end of the year? And can you update us on the exact status of XL and ER in Europe? And regarding the financials, they tend to stand a bit more the $40 million write down of the contingency for the Wellbutrin XL. What exactly was the accounting for this previously and is this a reduction of potential sample revenues that you have previously booked and can you give us some color of what the underlying accounting was for this?

    嗨,謝謝你。你提到一項研發審查。你能提供一下該審查的時間安排嗎?有可能在年底前拿到結果嗎?另外,你能更新一下 XL 與 ER 在歐洲的確切進度狀態嗎?再就財務面而言,大家似乎更關注 Wellbutrin XL 相關或有事項的 4,000 萬美元減記。先前這項目在會計上是如何處理的?這是否代表你們先前已入帳的潛在樣品收入被下修?能否說明一下其背後的會計處理基礎?

  • - CEO

    - CEO

  • Sure. Why don't we take the last one first and I'll ask Charlie to comment on that specific item.

    當然。我們先從最後一題開始,我請 Charlie 針對那個特定項目說明。

  • - SVP, CFO

    - SVP, CFO

  • Hi, Christine, this is Charlie. The question that you have on the sample allowance, the amount that was booked in the quarter really reflects the change in sample mix and forecasts of sample from GSK. If you recall in the previous quarter, we booked an amount for that and the big driver in that change was really evaluating the probability of when generics would come on the market and then also the significant change in sample mix that we received notification from from GSK. So that really drove those two amounts, the one being booked initially in the second quarter and now the additional 40 million this quarter.

    嗨,Christine,我是 Charlie。你問到的樣品備抵(sample allowance),本季入帳的金額主要反映樣品組合的變動,以及來自 GSK 的樣品預測變化。如果你還記得上一季,我們也為此入帳了一筆金額;那次變動的主要驅動因素,是我們重新評估學名藥何時會上市的可能性,以及我們收到 GSK 通知後樣品組合出現的重大變化。因此,這兩個因素驅動了兩筆金額:一筆是在第二季先行入帳,而本季再額外增加 4,000 萬美元。

  • - Analyst

    - Analyst

  • Right. But I'm just wondering why you have to book this. Is this previous revenue that you recognized?

    了解。但我只是想知道你們為什麼必須入帳這個。這是你們先前已認列的收入嗎?

  • - SVP, CFO

    - SVP, CFO

  • No, what this is this is just a loss contingency. It's non-cash. We may never pay this. If the generics are delayed and GSK continues to drawdown samples, we'll never actually make a payment to GSK. It's just part of the original contract that as they purchase the samples, this allowance would work down.

    不是,這其實是一項損失或有事項(loss contingency)。它是非現金項目。我們也可能永遠不需要支付這筆款項。如果學名藥上市延後,而 GSK 持續提領樣品,我們實際上就不會對 GSK 付款。這只是原始合約的一部分:當他們購買樣品時,這項備抵會逐步沖減。

  • - Analyst

    - Analyst

  • Okay.

    好的。

  • - CEO

    - CEO

  • Yes, and good morning, Christina, a couple of words, this R&D process and this R&D review that's ongoing as we speak and should be completed by the end of the year. What we can or will disclose about the out portion of that is dependent on the decisions that are made and what's added. We always have that dilemma about how explicit we can be on any of these and as much of these are related to proprietary technologies and ideas, but not necessarily related to composition of matter that provides the ability be disclosing, but we'll attempt to be as disclosing as we can, and as it relates to XL, Wellbutrin XL in other countries, Europe primarily, this is very active and files have been submitted I believe in Germany, Italy, and Spain and a variety of others are in preparation, so that's happening.

    是的,早安,Christina。我補充幾句:這個研發流程與研發審查目前正在進行中,預計會在年底前完成。至於我們能或將會揭露其中哪些結果,取決於所做出的決策以及新增了哪些內容。我們一向面臨一個兩難:在這些事項上我們能說得多明確;其中很多與專有技術與想法相關,但不一定是可讓我們放心揭露的「物質組成」層面的內容。不過我們會盡可能在可揭露的範圍內提供資訊。至於 XL、也就是 Wellbutrin XL 在其他國家(主要是歐洲)的進展,目前非常積極;我相信已在德國、義大利與西班牙遞交申請檔案,其他多個國家的資料也在準備中,所以這部分正在推進。

  • Ultram ER, with respect to other territories, were in sort of the final stages of discussion with OMI as to territories that they have and just in outside of the U.S, And that will be [Inaudible - audio difficulties], we'll be disclosing that.

    至於 Ultram ER,在其他地區方面,我們正與 OMI 就其在美國以外所擁有的地區權利進行接近最後階段的討論;而那將會[聽不清楚 - 音訊困難],我們也會對外揭露。

  • - Analyst

    - Analyst

  • Thank you. And one last question, you talked about potential outlicensing to accelerate the program. Is there certain programs that you're more likely to outlicense in others or is there programs that you would rather keep for yourself and generally, what would be your vision of what those outlicensing--?

    謝謝。最後一個問題,你提到可能透過對外授權來加速計畫。是否有某些計畫比其他計畫更可能被對外授權?或是有些計畫你們更想自己保留?整體而言,你們對這些對外授權的願景是什麼——?

  • - CEO

    - CEO

  • Generally, how we look at it is we're very interested talking to partners who have interest in some of our projects that are either in or about to go in Phase III, and what we think as a viable model is we've already proved ourselves. We've already proved ourselves on the ability to formulate. Formulation is not a worry for me. Our clinical development is very expensive and historically, we've funded that clinical development and waited until the end to do our agreement.

    整體來看,我們非常有興趣與對我們某些專案有興趣的合作夥伴洽談,特別是那些已在第三期或即將進入第三期的專案;我們認為可行的模式是:我們已經證明了自己。我們已經證明我們具備製劑能力。製劑對我而言不是問題。臨床開發非常昂貴,而過去我們通常是自行出資完成臨床開發,等到最後才簽訂合作協議。

  • We think now that for certain programs and one is a big Phase III and the Tramadol nonsteroidal would be an example of that and others where there's large Phase III trials, we can do an arrangement now if we have some cost sharing on the development side and preagree on a supply price that makes sense for both sides and we sort of bring maybe higher distant value into the near term, and preserve our ability to continue to drive forward our key program.

    我們現在認為,對某些專案而言——其中一個例子是大型第三期試驗,像是 Tramadol 非類固醇(nonsteroidal)那個專案,以及其他需要大型第三期試驗的專案——如果在開發端能有成本分攤,我們就可以現在就做安排,並事先談妥對雙方都合理的供應價格;如此一來,我們能把原本較遠期的價值部分拉近到近期,同時保留我們持續推進核心專案的能力。

  • - Analyst

    - Analyst

  • Okay, thank you.

    好的,謝謝。

  • - CEO

    - CEO

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Thank you. The following question is from David Lickrish of First Albany Capital. Please go ahead.

    謝謝。下一個問題來自 First Albany Capital 的 David Lickrish。請發問。

  • - Analyst

    - Analyst

  • Thank you very much and good morning. A couple easy ones, first I guess, Doug. Can you give us a PDUFA date for BVF 033, and I'm also just based on the guidance that you've given for the remainder of the year, it looks like if you look at the expenditures split between R&D and SG&A, that you're anticipating some sort of a relatively significant rebound.

    非常感謝,早安。幾個簡單的問題,首先我想問 Doug:你能提供 BVF 033 的 PDUFA 日期嗎?另外,根據你們對今年剩餘期間所給的指引來看,如果把研發(R&D)與銷售、一般及行政(SG&A)的支出拆開看,似乎你們預期支出會有相對明顯的回升。

  • I'm wondering if you could itemize for me what the SG&A and R&D expenses look like on a quarter-over-quarter basis, that is Q4 versus Q3, and then I'm interested in knowing, if you guys are moving forward on Phase III development of the combination Tramadol program plus an inset, does that mean that you have deferred or delayed what you want to do with the combination antidepressant plus SSSRI, Wellbutrin, that is, and are you partnering that out, that's obviously the stated preference here but you are moving forward with Tramadol. Are you doing the studies in parallel or are you waiting to complete one before starting the other? How are you going to proceed there.

    我想請你按季逐項說明 SG&A 與 R&D 費用的變化,也就是第四季相對第三季的情況;另外我也想了解,如果你們要推進 Tramadol 複方計畫加上一個 inset 的第三期開發,是否代表你們已遞延或延後你們對抗憂鬱藥複方加 SSSRI(也就是 Wellbutrin)的規劃?你們是否會把那個專案對外合作?這顯然是你們在此所表達的偏好,但你們正在推進 Tramadol。你們會並行進行研究,還是會等其中一個完成後再啟動另一個?你們打算如何推進?

  • - CEO

    - CEO

  • Yes, I'll take the last question first. The Tramadol combination in no way is related to the start time of the Bupropion combination so we will do those if we could do them contemporaneously, we would do them contemporaneously, so it relates to other things and the partner discussions and formulations and so on. It does not relate to that. Jumping back to your first question where you asked for the PDUFA date, I'm just going to ask Peter to state what that is because I can't read his writing across the room here. So he'll tell you.

    是的,我先回答最後一個問題。Tramadol 複方與 Bupropion 複方的啟動時間完全沒有關聯;因此如果我們能同時進行,我們就會同時進行,這取決於其他因素,例如合作夥伴洽談、製劑等。與那個無關。回到你第一個問題,你問 PDUFA 日期;我會請 Peter 直接說明,因為我在這裡看不清他寫的字。所以他會告訴你。

  • - SVP, Medical, Scientific Affairs

    - SVP, Medical, Scientific Affairs

  • July 28, 2007.

    2007 年 7 月 28 日。

  • - CEO

    - CEO

  • July 2007.

    2007 年 7 月。

  • - Analyst

    - Analyst

  • Right.

    對。

  • - CEO

    - CEO

  • And your middle question, would you repeat that again for me?

    至於你中間那個問題,你可以再重複一次嗎?

  • - Analyst

    - Analyst

  • Well, just based on the guidance that you've given for 2006, it looks like you are expending a bit of a rebound in expenditures of when you look at the combined lines of SG&A and R&D. I'm just wondering quarter-over-quarter what does SG&A look like? Is it relatively flat? Are you anticipating in the fourth quarter based on your guidance and is the preponderance of those funds all going to R&D? Just trying to get a sense of where we're going to exit 2006 for a run rate of 2007?

    嗯,根據你們對 2006 年的指引來看,把 SG&A 與 R&D 兩條線合併來看,似乎你們預期支出會有一些回升。我想了解按季來看 SG&A 會是什麼樣子?會相對持平嗎?依你們的指引,你們是否預期第四季會如此?而且這些資金的大部分是否都會投入到 R&D?我只是想掌握一下 2006 年結束時的支出水準,以便推估 2007 年的 run rate 會落在哪裡?

  • - CEO

    - CEO

  • I got it. I'm going to ask Charlie to maybe make a comment first.

    我了解了。我會請 Charlie 也許先發表一些評論。

  • - SVP, CFO

    - SVP, CFO

  • Yes, I think our R&D spending will go up in the fourth quarter, but as Doug talked about and I mentioned as well, we're expecting our other SG&A expenses to decrease or, at worse case you can model or maintain being flat with the third quarter because of the cost control initiatives that we've got in place. As Doug mentioned we're very, very prudent right now in filling open positions, initiating programs and projects, and as I also mentioned earlier on the call, in the first half of the year the run rate was higher because of all of the things we were doing related to governance, Sarbanes-Oxley compliance and some infrastructure upgrades.

    是的,我認為我們第四季的研發支出會上升,但正如 Doug 談到的以及我也提到的,我們預期其他 SG&A 費用會下降;或者在最壞情況下,因為我們已經推行的成本控管措施,你可以把它建模為與第三季持平。如 Doug 所提到的,我們目前在填補空缺職位、啟動計畫與專案方面都非常、非常審慎;另外我在電話會議前面也提過,上半年費用的執行率較高,是因為我們在公司治理、Sarbanes-Oxley 法案遵循以及一些基礎設施升級方面做了很多事情。

  • - Analyst

    - Analyst

  • All right I've got more questions but maybe I'll jump back in the queue and try and get in at the end.

    好的,我還有更多問題,但我可能先回到隊列後面,試著在最後再提問。

  • - CEO

    - CEO

  • Sure.

    當然。

  • Operator

    Operator

  • Thank you. The following question is from Andrew Swanson of Citigroup. Please go ahead.

    謝謝。下一個問題來自花旗集團(Citigroup)的 Andrew Swanson。請開始。

  • - Analyst

    - Analyst

  • Thanks very much and I apologize if you have addressed some of this already and we missed it, but I was hoping that we could walk through some of the Ultram revenue recognition. I know IMS I think reported sales in the quarter of something on the order of 28 million. Wondering what your view of end-user sales was and how that translates into what you're able to report and how we should think about that moving forward? I know there's a royalty step up in 2007, but even in the fourth quarter how we should think about revenue recognition for Biovail and then secondly, I was just wondering if you could comment on where we stand with partnering discussions on the new start for XL.

    非常感謝,也抱歉如果你們先前已經談到其中一些而我們錯過了,但我希望我們可以梳理一下 Ultram 的部分收入認列。我知道 IMS 似乎報告本季銷售額大約是 2,800 萬左右。想請教你們對終端用戶銷售(end-user sales)的看法是什麼,以及這如何轉換成你們能夠報告的數字,我們未來應該如何看待?我知道 2007 年權利金會有一個上調(royalty step up),但即使在第四季,我們應該如何看待 Biovail 的收入認列?另外第二點,我想請你們評論一下,我們在 XL 新啟動項目的合作夥伴洽談目前進展到哪裡。

  • - CEO

    - CEO

  • Okay I'll take the last one first and then I'll ask Charlie to comment on revenue recognition with respect to Ultram ER. There are partnering discussions ongoing with salt and hopefully we'll come to a good deal and then we will disclose it.

    好的,我先回答最後一個問題,然後我會請 Charlie 就 Ultram ER 的收入認列做評論。目前與 Salt 的合作夥伴討論仍在進行中,希望我們能達成一個好的交易,之後我們會予以揭露。

  • - Analyst

    - Analyst

  • I'm sorry to interrupt but does Glaxo have any sort of right of first refusal or anything of that nature?

    抱歉打斷一下,但 Glaxo 是否有任何優先承購權(right of first refusal)或類似性質的權利?

  • - CEO

    - CEO

  • They have no right of first refusal in the contract. Charlie, do you want to comment on revenue recognition in the fourth quarter?

    他們在合約中沒有任何優先承購權。Charlie,你要不要評論一下第四季的收入認列?

  • - SVP, CFO

    - SVP, CFO

  • Yes, Andrew, I think I mentioned this on our earlier call when we set guidance for this year and so fourth. Our revenue recognition and our guidance for Ultram ER basically, we recognize revenue when we ship products to OMI and our guidance includes their safety stock, their inventory in the trade, and then what is also pulled through in the marketplace. So all of those things are reflected in our numbers because we don't manage that, OMI does, so we record the revenue when we ship to them.

    好的,Andrew,我想我在我們先前那通電話、我們為今年等設定財測指引時提過這點。就 Ultram ER 而言,我們的收入認列以及指引基本上是:當我們把產品出貨給 OMI 時就認列收入;而我們的指引包含他們的安全庫存(safety stock)、通路中的庫存,以及市場端實際拉貨(pulled through)的部分。因為我們不管理那些,OMI 才管理,所以這些都反映在我們的數字裡;我們在出貨給他們時就入帳收入。

  • - Analyst

    - Analyst

  • I guess another way to ask the question would be--At what point, is it fourth quarter, is it first quarter, second quarter 2007, at what point, I mean ultimately if that's the case, your revenues should essentially track with end-user sales whatever those ultimately are. I mean, when do you think we get to a point where those two figures start to move in parallel?

    我想換個方式問——在什麼時間點,是第四季、2007 年第一季、第二季的哪個時點?我的意思是,最終如果是這樣,你們的營收應該基本上會跟終端用戶銷售(不論最終是多少)一致。你們認為什麼時候這兩個數字會開始平行變動?

  • - SVP, CFO

    - SVP, CFO

  • I would say you could model first quarter of next year would be a good time because if I were doing a projection going forward, those would start to align very nicely.

    我會說你可以把明年第一季作為一個不錯的時間點來建模,因為如果我在做未來的預測,從那時起兩者會開始非常好地對齊。

  • - Analyst

    - Analyst

  • Perfect. Thanks very much.

    太好了。非常感謝。

  • - SVP, CFO

    - SVP, CFO

  • Okay.

    好的。

  • Operator

    Operator

  • Thank you. The following question is from Hari Sambasivam of Merrill Lynch. Please go ahead.

    謝謝。下一個問題來自美林(Merrill Lynch)的 Hari Sambasivam。請開始。

  • - Analyst

    - Analyst

  • Yes, thank you. A couple of quick questions. One for Doug. Doug, in terms of the Ultram strategy at this point in time, I know you're increasing your investment in terms of advertising and promotion. Is that simply an issue of more money or is there a different positioning or a different targeting that is involved in this particular issue. That's the first question. Second question relates to essentially pipeline strategy.

    是的,謝謝。兩個簡短問題。第一個給 Doug。Doug,就目前 Ultram 的策略而言,我知道你們正在增加廣告與推廣方面的投資。這純粹只是多花錢的問題,還是涉及不同的定位或不同的目標客群?這是第一個問題。第二個問題基本上與產品線(pipeline)策略有關。

  • I know you have a review ongoing but what I want to know is where are you sort of wanting to end up here? Is there still going to be a specialty type of approach in terms of what fits into your own salesforce or is this more opportunistic where we might see multiple different products come out of this pipeline review and an associated question is--What's happening to Ambien, the flash dose Ambien product? Thank you.

    我知道你們正在進行一項檢視,但我想知道你們希望最後達到什麼樣的狀態?在是否符合你們自有銷售團隊的產品方面,是否仍會採取專科型(specialty)的方式?還是這會更偏機會導向(opportunistic),我們可能會看到多個不同產品從這次產品線檢視中產出?以及一個相關問題是——Ambien,也就是 Ambien 的快溶劑量(flash dose)產品,目前進展如何?謝謝。

  • - CEO

    - CEO

  • Okay, good morning, Hari. Firstly, Ultram ER, is it a question about money? It's not so much more money. It's promotion in areas that we seem to be effective and assisting OMI and providing more weight on that when we have an opportunity to do that. Just a couple of comments on Ultram ER, when we look at performance year-to-date. One of the interesting things maybe I'd suggest people look at is most of the analogs that we used and others have used, our products were introduced that had both an acute and a chronic claim.

    好的,早安,Hari。首先,關於 Ultram ER,這是錢的問題嗎?不完全是更多的錢。而是在我們看起來有效的領域加強推廣,協助 OMI,並在有機會時在這些方面加大力度。再補充幾點關於 Ultram ER:當我們看今年迄今的表現時,有一件有趣的事,我可能會建議大家去看一下:我們以及其他人過去使用的大多數類比案例,都是推出同時具有急性與慢性適應症主張(acute and chronic claim)的產品。

  • And that seemed reasonable at the time and then we had some conversion stuff and so on, but as we've looked at it and as we've talked to patient doctors and seen the results, we begin to think that this chronic pain market is maybe a little different than that, and it's quite interesting if you go and look at drugs that have been introduced in the past few years that have a chronic pain indication only, and those would be things like Duragesic and Oxycontin and others, and look at their update rates, so an example of that would be Duragesic whose uptake -- we're way ahead of Duragesic's initial update rates, but Duragesic is a very significant, very high value drug and it's also an OMI drug, so it's interesting to think of it that -- so we start to think that getting the right patient in, getting that patient that's not got that sort of maybe intermittent pain that doctors aren't necessarily used to prescribing this once a day type of product or that that person that needs that medicine every day, the DTC is directed towards that. The sampling change is directed towards that and so on, so we're -- we're still -- we think the jury is still out here so we feel pretty optimistic about that.

    當時這看起來合理,之後我們也做了一些轉換(conversion)等工作;但隨著我們進一步研究、與病患與醫師交流並看到結果,我們開始認為慢性疼痛市場可能有點不同。若你回頭看過去幾年推出、僅有慢性疼痛適應症(chronic pain indication only)的藥物,其實很有意思;例如 Duragesic、Oxycontin 等,並觀察它們的導入速度(uptake rates)。以 Duragesic 為例,我們的導入速度遠遠領先 Duragesic 初期的導入速度;但 Duragesic 是一個非常重要、價值很高的藥物,而且也是 OMI 的產品,所以這樣比較也很有意思。於是我們開始認為:讓合適的病患進來、找到那種不是間歇性疼痛(intermittent pain)的病患——因為醫師未必習慣為這類病患開立這種每日一次(once a day)的產品——而是那種每天都需要用藥的人;我們的 DTC(直接面向消費者)就是針對這點。試用品(sampling)的調整也是針對這點,等等;所以我們——我們仍然——我們認為目前還言之過早(jury is still out),因此我們對此相當樂觀。

  • Let's see, I have to read my writing here since I talked so long. Your pipeline is right and about just sort of maybe giving some sense of it, I think there's two things I'd say to that, Hari. One is that our pipeline, internal pipeline, will always be based or is intended always to be based on our difficult to manufacture, high-technology, value add additions to drugs. That is sort of an underlying core strategic platform of the Company; however, I think we certainly would look at this review that it's undergoing as being -- ensuring that we look at all of the opportunities in all of the spaces out there that are important, an example would be oh, I don't know, difficult to manufacture generics, for example, as opposed to taking an NC and making it once a day to three times a day. Both use technologies and so I think we would certainly maybe expand the base a little bit but it will always be based on the technology platform that we have. And your third question, Hari?

    我看看,我講太久了,得讀一下我寫的筆記。你關於產品線的問題是對的;就大致給一些方向感而言,Hari,我想我會說兩點。第一,我們的產品線——內部產品線——將永遠以、或說其設計初衷永遠是以我們「難以製造(difficult to manufacture)、高科技(high-technology)、具附加價值(value add)」的藥物改良為基礎。這是公司一個底層的核心策略平台;不過,我認為我們也會把這次正在進行的檢視視為——確保我們能檢視外部所有重要領域中的各種機會;例如,嗯,我不知道,像是難以製造的學名藥(difficult to manufacture generics),而不是把一個 NC 做成每日一次到每日三次。兩者都會用到技術,因此我認為我們可能會稍微擴大基礎,但永遠會以我們現有的技術平台為根基。那你的第三個問題是什麼,Hari?

  • - Analyst

    - Analyst

  • Was Ambien.

    是 Ambien。

  • - CEO

    - CEO

  • Yes. With Ambien ODT, we are in discussions with a potential partner for that product as we speak.

    是的。就 Ambien ODT 而言,我們此刻正與一位潛在合作夥伴就該產品進行洽談。

  • - Analyst

    - Analyst

  • Thank you.

    謝謝。

  • - CEO

    - CEO

  • Thank you, Hari.

    謝謝你,Hari。

  • Operator

    Operator

  • Thank you. The following question is from Jeff Elliott of UBS Securities. Please go ahead.

    謝謝。下一個問題來自 UBS Securities 的 Jeff Elliott。請開始。

  • - Analyst

    - Analyst

  • Thanks. I just had a quick question on the R&D. You guided to 110 to 120 million for 2006 on your last quarter and it looks like you're tracking well below that. Is that a timing issue, i.e. the fourth quarter will spike up and then you'll see more in the first quarter or does it have anything to do with the outlicensing strategy? Have you changed your view on the pipeline and the investment in that at all?

    謝謝。我有個關於研發(R&D)的簡短問題。你們在上一季指引 2006 年為 1.10 億到 1.20 億美元,但看起來目前的進度遠低於該區間。這是時點問題嗎?也就是第四季會跳升,然後第一季會看到更多?還是與對外授權策略有關?你們對研發管線以及相關投資的看法有任何改變嗎?

  • - CEO

    - CEO

  • No, and I think it's fundamentally a timing issue. The big variables in that are generally things related to clinical Phase III, when they start and when the investigators come on board and when the patient is in that sort of thing and that tends to make it a little spikey.

    沒有,我認為基本上是時點問題。其中最大的變動因素通常與臨床三期(Phase III)相關:何時啟動、研究者何時加入、病患何時入組之類的,這些往往會讓費用呈現較為尖峰的波動。

  • - Analyst

    - Analyst

  • Okay, great. Thanks.

    好的,很好。謝謝。

  • Operator

    Operator

  • Thank you. The following question is from John Maletic of Scotia Capital. Please go ahead.

    謝謝。下一個問題來自 Scotia Capital 的 John Maletic。請開始。

  • - Analyst

    - Analyst

  • Hi, good morning. Just a couple questions. First on the Wellbutrin salt, I understand that you're in discussions for partnering right now. Is that at all contingent on the timing of the generic release of the product and specifically, will a potential partner be willing to commit a salesforce to such a follow-on product once generic penetration has already started? And secondly, I didn't get the comments on the situation with Wellbutrin in Europe and I was wondering if you could just review that.

    嗨,早安。有幾個問題。首先關於 Wellbutrin 的鹽類(salt),我了解你們目前正在洽談合作。這是否取決於該產品學名藥上市的時點?具體來說,一旦學名藥滲透已經開始,潛在合作夥伴是否仍願意為這種後續產品投入銷售團隊?第二,我沒有聽清楚你們對 Wellbutrin 在歐洲情況的評論,想請你們再回顧說明一下。

  • - CEO

    - CEO

  • Sure. Firstly on the salt, clearly, it's not independent of the generic but we believe strongly that the salt has value in and of itself for some of the safety reasons associated with this formulation and some of which we haven't disclosed so we do believe it has legs on it's own and are confident that others will see it that way as well. In terms of Wellbutrin XL Europe, as I mentioned, the product has been submitted in Germany, Italy, and Spain, and other countries are actively in preparation for those.

    當然。先談鹽類:很明顯它並非與學名藥完全無關,但我們堅信該鹽類本身具有價值,部分原因在於此配方相關的一些安全性因素,其中有些我們尚未揭露;因此我們確實相信它本身就站得住腳,也有信心其他人也會以同樣方式看待。至於 Wellbutrin XL 在歐洲,如我提到的,該產品已在德國、義大利與西班牙遞交申請,其他國家也正積極準備中。

  • - Analyst

    - Analyst

  • Okay. And then just one more final question. For the major part of the intangible write-off, what was that related to?

    好的。再一個最後的問題。無形資產減損(write-off)中占最大部分的是與什麼相關?

  • - SVP, Medical, Scientific Affairs

    - SVP, Medical, Scientific Affairs

  • The major portion of the intangible write-off was related to Vasotec.

    無形資產減損的主要部分與 Vasotec 有關。

  • - Analyst

    - Analyst

  • Okay. Thanks.

    好的。謝謝。

  • - CEO

    - CEO

  • Thank you.

    謝謝。

  • Operator

    Operator

  • The last question is from David Lickrish of First Albany Capital. Please go ahead.

    最後一個問題來自 First Albany Capital 的 David Lickrish。請開始。

  • - Analyst

    - Analyst

  • Thanks for taking the follow-up, guys. I want to understand this because I think it's very important. Are you suggesting with the current ANDA with Wellbutrin XL that some of the amendments that were filed with respect to the generic caused the product to further infringe upon your formulations? And how is that process going to play out, because it obviously is going to impact the timing of generic.

    謝謝讓我追問,各位。我想弄清楚這點,因為我認為非常重要。你們是否在暗示,就目前 Wellbutrin XL 的 ANDA 而言,針對學名藥所提交的一些修正案,導致該產品進一步侵害你們的配方?而這個流程將如何發展?因為顯然會影響學名藥上市的時點。

  • - CEO

    - CEO

  • I guess a fundamental basis of that citizens petition is that if you certify, you don't change the product. Historically there have been multiple examples because the first status is is so valuable from a generic perspective that they file as soon as they possibly can, even though one might not have a scalable product, a product that can be efficiently and effectively manufactured, and then you have a whole series of changes that in fact radically change the nature and whether that, those changes infringe the patent or not, it's certainly possible the changes that would be made subsequent and whether those changes result in actual changes in the release characteristics of the product or the release characteristics of the product in alcohol or whether they fundamentally might change the bioequivalents of metabolites compared to the XL and the SR and the IR. All of those things are possible and so that's why we feel strongly about our position on post-certification changes in manufacturing and formulation.

    我想該公民請願(citizens petition)的基本立場是:一旦你做出認證(certify),就不應更改產品。歷史上有多個例子,因為「首家」地位對學名藥而言價值極高,所以他們會在可能的最早時間提出申請,即便當時可能還沒有可擴產的產品、也就是無法有效率且有效地製造的產品;接著就會出現一連串變更,而這些變更事實上會大幅改變產品的性質。至於那些變更是否侵害專利,當然是有可能的;後續所做的變更是否會造成產品釋放特性改變、或在酒精環境下的釋放特性改變,或是否從根本上改變代謝物相對於 XL、SR 與 IR 的生體相等性(bioequivalence),這些都有可能。因此,我們才會強烈主張:在認證之後對製造與配方所做的變更應被嚴肅看待。

  • - Analyst

    - Analyst

  • Okay. And then just finally I'll sneak it in. When you're going to partners with some of your combination products right now, can you maybe very generally describe for me the data that you're able to present to them in terms of validating, I think conceptually it's a very good idea but it's something to give them comfort around the feasibility?

    好的。最後我再插問一下。你們目前在為一些複方產品尋找合作夥伴時,能否非常概括地描述一下,你們能向他們呈現哪些數據來驗證可行性?我在概念上覺得這是很好的想法,但他們需要一些東西來增加對可行性的信心。

  • - CEO

    - CEO

  • Sure. I mean these types of presentations in a broadest sense contain two components. They contain our commercial assessment of the opportunity and we do a very rigorous commercial assessment and we have people inside that do that and we also use external people and external consultants and we make their commentary and so on available to the potential partner, so we don't ask them to say, do you think this has commercial value. We go in and present in detail and we did this by the way just a few days ago, in detail, what the commercial value-add is.

    當然。我想這類簡報在最廣義上包含兩個部分。第一部分是我們對機會的商業評估;我們會做非常嚴謹的商業評估,內部有專人負責,也會使用外部人士與外部顧問,並把他們的評論等提供給潛在合作夥伴,因此我們不會只是問他們「你覺得這有商業價值嗎」。我們會進去做詳細簡報;順帶一提,我們就在幾天前做過一次,詳細說明其商業加值(value-add)是什麼。

  • The second component is, and it depends on the product and where it is in our development, would be a review of the clinical development plan and that's where Peter Silverstone and others would be giving the details of the plan, the rationale for the plan, the size of the trial, location of the trial, et cetera et cetera. The timing of the filings, the timing of the analysis, and so on. So they are usually very detailed and two, three hour presentations and they are always well attended and the ones we've made recently have been well received.

    第二部分則取決於產品以及其在我們開發中的階段,會是對臨床開發計畫的檢視;由 Peter Silverstone 與其他人說明計畫細節、計畫的理據、試驗規模、試驗地點等等。申報時程、分析時程等等。因此通常是非常詳細、兩到三小時的簡報,而且總是有很多人出席;我們最近做的幾場也都獲得良好回饋。

  • - Analyst

    - Analyst

  • Thanks very much.

    非常感謝。

  • - CEO

    - CEO

  • Sure, David, thanks.

    當然,David,謝謝。

  • Operator

    Operator

  • Thank you. This concludes today's question and answer session. I would now like to turn the meeting over to Dr. Squires for closing remarks.

    謝謝。今天的問答環節到此結束。我現在想把會議交給 Squires 博士作結語。

  • - CEO

    - CEO

  • Okay, thanks very much. Again, I Appreciate your attending this morning. I would like to take this opportunity to express my personal thanks to all of Biovail's employees whose hard work and diligent efforts has resulted in another exceptional quarter for Biovail. Thank you very much.

    好的,非常感謝。再次感謝各位今天早上出席。我想藉此機會,向所有 Biovail 員工表達我個人的感謝;他們的辛勤工作與勤勉努力,讓 Biovail 再次交出一個卓越的季度。非常謝謝。

  • Operator

    Operator

  • Thank you, gentlemen. The conference has now ended. Please disconnect your lines at this time. We thank you all for your participation and have a great day.

    謝謝各位先生。本次電話會議現在結束。請各位此時掛斷電話線。感謝各位的參與,祝各位有美好的一天。